EYEPOINT PHARMACEUTICALS INC (EYPT) Stock Price, Quote, News and Overview
NASDAQ:EYPT - Nasdaq - US30233G2093 - Common Stock - Currency: USD
EYPT Quote, Performance and Key Statistics
6.25
-0.61 (-8.89%)
The current stock price of EYPT is 6.25 USD. In the past month the price increased by 35.28%. In the past year, price decreased by -48.3%.
EYPT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 56.33 | 734.81B | ||
| JNJ | JOHNSON & JOHNSON | 15.37 | 371.67B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.21 | 294.26B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.3 | 218.35B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.89 | 217.83B | ||
| MRK | MERCK & CO. INC. | 10.15 | 198.90B | ||
| SNY | SANOFI-ADR | 13.81 | 130.11B | ||
| PFE | PFIZER INC | 7.13 | 129.76B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.48 | 96.81B | ||
| GSK | GSK PLC-SPON ADR | 6.86 | 75.88B | ||
| ZTS | ZOETIS INC | 25.32 | 66.85B | ||
| HLN | HALEON PLC-ADR | 21.78 | 48.11B |
Related stock screener links
About EYPT
Company Profile
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. The company is headquartered in Watertown, Massachusetts and currently employs 165 full-time employees. The company went IPO on 2005-01-27. The firm is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
Company Info
EYEPOINT PHARMACEUTICALS INC
480 Pleasant St Ste B300
Watertown MASSACHUSETTS 02472 US
CEO: Nancy Lurker
Employees: 165
Phone: 16179265000
EYEPOINT PHARMACEUTICALS INC / EYPT FAQ
What is the stock price of EYEPOINT PHARMACEUTICALS INC today?
The current stock price of EYPT is 6.25 USD. The price decreased by -8.89% in the last trading session.
What is the ticker symbol for EYEPOINT PHARMACEUTICALS INC stock?
The exchange symbol of EYEPOINT PHARMACEUTICALS INC is EYPT and it is listed on the Nasdaq exchange.
On which exchange is EYPT stock listed?
EYPT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EYEPOINT PHARMACEUTICALS INC stock?
19 analysts have analysed EYPT and the average price target is 33.66 USD. This implies a price increase of 438.56% is expected in the next year compared to the current price of 6.25. Check the EYEPOINT PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EYEPOINT PHARMACEUTICALS INC worth?
EYEPOINT PHARMACEUTICALS INC (EYPT) has a market capitalization of 430.06M USD. This makes EYPT a Small Cap stock.
How many employees does EYEPOINT PHARMACEUTICALS INC have?
EYEPOINT PHARMACEUTICALS INC (EYPT) currently has 165 employees.
Is EYEPOINT PHARMACEUTICALS INC (EYPT) expected to grow?
The Revenue of EYEPOINT PHARMACEUTICALS INC (EYPT) is expected to decline by -42.39% in the next year. Check the estimates tab for more information on the EYPT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EYEPOINT PHARMACEUTICALS INC (EYPT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EYPT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EYPT, evaluating the profitability, health, valuation and growth aspects
- EYEPOINT PHARMACEUTICALS INC (EYPT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EYEPOINT PHARMACEUTICALS INC (EYPT) Sales and EPS estimates to see what analysts future expectations are.
- EYEPOINT PHARMACEUTICALS INC (EYPT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EYEPOINT PHARMACEUTICALS INC (EYPT) Insider and Institutional Ownership to learn about the owners and their transactions.
- EYEPOINT PHARMACEUTICALS INC (EYPT) Stock Chart to make your own analysis
- EYEPOINT PHARMACEUTICALS INC (EYPT) Latest news and press-releases to stay up to date.
Does EYEPOINT PHARMACEUTICALS INC (EYPT) stock pay dividends?
EYPT does not pay a dividend.
When does EYEPOINT PHARMACEUTICALS INC (EYPT) report earnings?
EYEPOINT PHARMACEUTICALS INC (EYPT) will report earnings on 2025-05-07.
What is the Price/Earnings (PE) ratio of EYEPOINT PHARMACEUTICALS INC (EYPT)?
EYEPOINT PHARMACEUTICALS INC (EYPT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.31).
What is the Short Interest ratio of EYEPOINT PHARMACEUTICALS INC (EYPT) stock?
The outstanding short interest for EYEPOINT PHARMACEUTICALS INC (EYPT) is 18.23% of its float. Check the ownership tab for more information on the EYPT short interest.
EYPT Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to EYPT. When comparing the yearly performance of all stocks, EYPT is a bad performer in the overall market: 81.87% of all stocks are doing better.
EYPT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to EYPT. EYPT has a great financial health rating, but its profitability evaluates not so good.
EYPT Financial Highlights
Over the last trailing twelve months EYPT reported a non-GAAP Earnings per Share(EPS) of -2.31. The EPS decreased by -26.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.27% | ||
| ROE | -38.89% | ||
| Debt/Equity | 0 |
EYPT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to EYPT. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of -21.15% and a revenue growth -42.39% for EYPT